An overview of cytokines and cytokine antagonists as therapeutic agents

Annals of the New York Academy of Sciences

Volumn 1182, Issue , 2009, Pages 1-13

  Donnelly, Raymond P ^a   Young, Howard A ^b   Rosenberg, Amy S ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cytokines; Inflammation; Interferons; Interleukins; Receptors

Indexed keywords

ALPHA INTERFERON; CONSENSUS INTERFERON; CYTOKINE; CYTOKINE RECEPTOR ANTAGONIST; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 29; INTERLEUKIN 7; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT BETA INTERFERON; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 21; RIBAVIRIN; RILONACEPT; RITUXIMAB; STIBOGLUCONATE SODIUM; TRASTUZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB;

ALBERS SCHOENBERG DISEASE; ANEMIA; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ATYPICAL MYCOBACTERIOSIS; AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; BIOENGINEERING; BONE MARROW SUPPRESSION; BREAST CANCER; CHILL; CHRONIC GRANULOMATOUS DISEASE; CINCA SYNDROME; CLINICAL TRIAL; COLON ADENOCARCINOMA; CONFERENCE PAPER; CROHN DISEASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOLERABILITY; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FEVER; FOOD AND DRUG ADMINISTRATION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; KIDNEY CARCINOMA; MELANOMA; MUCKLE WELLS SYNDROME; MULTIPLE SCLEROSIS; NAUSEA; NEOPLASM; NEUTROPENIA; NONHUMAN; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; THROMBOCYTOPENIA; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

HARNESS;

EID: 73849119978     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05382.x     Document Type: Conference Paper

References (30)

1. Kühn R, J. Löhler, D. Rennick, K. Rajewsky & W. Müller. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-274.
2. Bickston, S.J. & F. Cominelli. 2000. Recombinant interleukin-10 for the treatment of active Crohn's disease: lessons in biologic therapy. Gastroenterology 119: 1781-1783.
3. Sheppard, P. et al. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4: 63-68.
4. Kotenko, S.V. et al. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4: 69-77.
5. Brideau-Andersen, A.D. et al. 2007. Directed evolution of gene-shuffled IFN-alpha molecules with activity profiles tailored for treatment of chronic viral diseases. Proc. Natl. Acad. Sci. USA 104: 8269-8274.
6. Miller, D.M. et al. 2009. Interferon lambda (IFN-ë) as a potential new therapeutic for hepatitis C. Ann. N. Y. Acad. Sci. 1182: 80-87.
7. Doyle, S.E. et al. 2006. Interleukin-29 uses a type-1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44: 896-906.
8. Marcello, T. et al. 2006. Interferons α and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131: 1887-1898.
9. Miller, C.H.T., S.G. Maher & H.A. Young. 2009. Clinical use of interferon-aγ. Ann. N. Y. Acad. Sci. 1182: 69-79.
10. Holland S.M. 2007. Interferon gamma, IL-12, IL-12R and STAT1 immunodeficiency diseases: Disorders of the interface of innate and adaptive immunity. Immunol. Res. 38: 342-346.
11. Ward, C.M. et al. 2007. Adjunctive treatment of disseminated Mycobacterium avium complex infection with interferon alpha-2b in a patient with complete interferon-gamma receptor R1 deficiency. Eur. J. Pediatr. 166: 981-985.
12. Sport̀es, C., R.E. Gress & C.L. Mackall. 2009. Perspective on potential clinical applications of recombinant human interleukin-7. Ann. N. Y. Acad. Sci. 1182: 28-38.
13. Chavez, A.R. et al. 2009. Pharmacologic administration of interleukin-2: inducing a systemic autophagic syndrome? Ann. N. Y. Acad. Sci. 1182: 14-27.
14. Sabatino, M. et al. 2009. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J. Clin. Oncol. 27: 2645-2652.
15. Tarhini, A.A. & J.M. Kirkwood. 2009. Clinical and immunologic basis of interferon therapy in melanoma. Ann. N. Y. Acad. Sci. 1182 47-57.
16. Franzke, A. et al. 1999. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J. Clin. Oncol. 17: 529-533.
17. Gogas, H. et al. 2006. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354: 709-718.
18. Fan, K., E. Borden & T. Yi. 2009. Interferon-gamma is induced in human peripheral blood immune cells in vitro by sodium stibogluconate/ interleukin-2 and mediates its anti-tumor activity in vivo. J. Interferon Cytokine Res. 29: 451-460.
19. Bhave, N.S. &W.E. Carson III. 2009. Immune modulation with interleukin-21. Ann. N. Y. Acad. Sci. 1182: 39-46.
20. Scheinecker, C., K. Redlich & J.S. Smolen. 2008. Cytokines as therapeutic targets: Advances and limitations. Immunity 28: 440-444.
21. Moreland, L.W. 2009. Cytokines as targets for antiinflammatory agents. Ann. N. Y. Acad. Sci. 1182: 88-96.
22. Elliott, M. et al. 2009. Ustekinumab: lessons learned from targeting IL-12/23p40 in immune-mediated diseases. Ann. N. Y. Acad. Sci. 1182: 97-110.
23. Rani, M.R.S. et al. 2009. Heterogeneous, longitudinally-stable molecular signatures in response to interferon-β. Ann. N. Y. Acad. Sci. 1182: 58-68.
24. Chaussabel, D. et al. 2008. A modular analysis framework for blood genomics studies: Application to systemic lupus erythematosus. Immunity 29: 150-164.
25. Goldbach-Mansky, R. 2009. Blocking interleukin-1 in rheumatic diseases: its initial disappointments and recent successes in the treatment of autoinflammatory diseases. Ann. N. Y. Acad. Sci. 1182: 111-123.
26. Stahl, N., A. Radin & S. Mellis. 2009. Rilonacept-CAPS and beyond: A scientific journey. Ann. N. Y. Acad. Sci. 1182: 124-134.
27. Abuchowski, A., J.R. McCoy, N.C. Palczuk, T. van Es & F.F. Davis. 1977. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 252: 3582-3586.
28. Steidler, L., P. Rottiers & B. Coulie. 2009. ActobioticsTM as a novel method for cytokine delivery: The interleukin-10 case. Ann. N. Y. Acad. Sci. 1182: 135-145.
29. Steidler, L., W. Hans, L. Schotte, et al. 2000. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289: 1352-1355.
30. Kozlowski, S., B. Cherney & R.P. Donnelly. 2009. Hurdles and leaps for protein therapeutics: Cytokines and inflammation. Ann. N. Y. Acad. Sci. 1182: 146-160.